Latest return on equity
TransCode Therapeutics Return on equity
TransCode Therapeutics (RNAZ) return on equity with its verified observation da…
Direct answer
TransCode Therapeutics's return on equity is -59.28%.
The verified market snapshot reports -59.28%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked September 1, 2026.
Get free TransCode Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Return on equity
- -59.28%
Explore related company data
View TransCode Therapeutics's market capitalizationView TransCode Therapeutics's price-to-book ratioView TransCode Therapeutics's 52-week price rangeView TransCode Therapeutics's profit marginView TransCode Therapeutics's debt-to-equity ratioView all TransCode Therapeutics key metricsReturn to TransCode Therapeutics profile